

ONCONNECTION: 2021-2023
IL CANCRO AL TEMPO DEL COVID

GIOVEDÌ 18 FEBBRAIO 2021



Valentina Guarneri
Professore Università di Padova,
Oncologia 2 Istituto Oncologico Veneto

European Journal of Cancer xxx (xxxx) xxx



Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejcancer.com



Original Research

Epidemiology and clinical course of SARS-CoV-2 infection in patients with cancer in the Veneto Oncology Network: The ROVID study

Valentina Guarneri ^{a,b}, Franco Bassan ^c, Vittorina Zagonel ^d,
Michele Milella ^e, Marta Zaninelli ^f, Anna M. Cattelan ^g,
Andrea Vianello ^h, Stefania Gori ⁱ, Giuseppe Aprile ^j,
Giuseppe Azzarello ^k, Rita Chiari ^l, Adolfo Favaretto ^m, Cristina Oliani ⁿ,
Annamaria Scola ^o, Davide Pastorelli ^p, Marta Mandarà ^q,
Fable Zustovich ^r, Daniele Bernardi ^s, Vanna Chiarion-Sileni ^t,
Paolo Morandi ^u, Silvia Toso ^v, Elisabetta Di Liso ^a, Stamatia Ziampiri ^c,
Mario Caccese ^d, Ilaria Zampiva ^e, Oliviero Puccetti ^c, Michele Celestino ^a,
Maria V. Dieci ^{a,b}, PierFranco Conte ^{a,b,*} on behalf of the Veneto
Oncology Network

PAZIENTI ONCOLOGICI E PANDEMIA SARS-CoV-2:
PDTA DELLA RETE ONCOLOGICA VENETA



Edizione 1ª - Aprile 2020



Ensure proper care

Minimizing the risk of infection in cancer patients
and **Staff**

Epidemiology and clinical course of SARS-CoV-2 infection
in cancer patients in the Veneto Oncology Network: The
ROVID Study

- 26 participating centers under the coordination of the ROV
- Observational study.
- Supported by a grant of Fondazione CARIPARO

The ROVID Study: Results

Total patients (N): 170

Active anticancer therapy	N (%)
Yes	89 (52.4)
Yes – Curative intent	22 (24.7)
Yes – Palliative intent	67 (75.3)
No	81 (47.6)

Treatment discontinuation rate because of SARS-CoV-2 infection: 68%

	N (%)
With symptoms	131 (78)
Asymptomatics	32 (19)
By radiological findings	5 (3)


Type of contact	N (%)
In-hospital	41 (24)
Extra-hospital	44 (26)
Unknown	85 (50)

Hospitalization	N (%)
Yes	132 (77)
Yes – Intensive care unit	10 (6)
No	38 (23)

RESULTS: association between clinical-laboratory factors with the risk of death

Resolution of infection	N (%)
Yes (two consecutive negative nasopharyngeal swab)	103 (77)
No - Death	57 (33)
Death for SARS-CoV-2	29 (17)

	OR	95% CI	p value
ECOG PS (≥ 2 vs 0-1)	4.286	2.001-9.183	<0.001
AGE (per 1 year increment)	1.030	1.003-1.057	0.030
2 or MORE COMORBIDITIES (vs 0-1)	2.005	1.047-3.839	0.036
DYSPNOEA (yes vs no)	5.956	2.959-11.989	0.001
CLINICAL PHENOTYPE (≥ 3 vs 1-2)	6.006	2.793-12.915	0.001
HOSPITALIZATION (yes vs no)	4.290	1.573-11.700	0.004
ICU ADMISSION (yes vs no)	9.061	1.856-44.236	0.006
NEUTROPHILS/LYMPHOCYTES RATIO (≥ 7 vs <7)	7.669	3.097-18.990	0.001
TROMBOCYTOPENIA (<150.000 vs ≥ 150.000)	2.770	1.306-5.876	0.008



Smoking status, Hypertension, Treatment setting, Presence of Lung Metastasis and Chemoterapy were not associated with increased risk of death.

CONCLUSIONS AND PERSPECTIVES

- Mortality rate in line with other registry of cancer patients -> Frailty of this population
- Need to protect cancer patients from SARS-CoV-2 infection
- Data collection still ongoing: 440 cases registered as of 10 Feb 2021
- Preliminary analyses comparing patients diagnosed during first and second pandemic wave reinforce the need to proactively protect cancer patients from SARS-CoV-2 infection (data submitted ASCO 2021)